Caidya
Manages clinical trials and regulatory strategy for biopharmaceutical companies.
Company facts
- Founded
- 2003
- Employees
- 1,800
- Headquarters
- United States
- CEO
- Barbara Lopez Kunz
- Type
- Private
- Funding
- Private Equity · $165M · 2024
- Subsidiaries
- Clinipace, dMed Global, Target Health, Accovion
About
Caidya is a global, multi-therapeutic clinical research organization (CRO) that aims to activate the full potential of scientific innovations through personalized partnerships. Formed in 2021 from the merger of dMed and Clinipace, Caidya combines the strengths and expertise of both companies to provide comprehensive clinical development services across various therapeutic areas. The organization is dedicated to facilitating efficient clinical trials that accelerate the delivery of novel therapeutics to patients worldwide. With nearly 1,800 professionals located in more than 30 countries, Caidya leverages its expansive global expertise and advanced technologies to enhance the clinical research process. By offering tailored solutions—from early phase development to regulatory submissions—Caidya is committed to improving patient access to groundbreaking treatments. The company emphasizes transparency and data-driven decision-making, which helps stakeholders navigate the complexities of clinical trials effectively. Ultimately, Caidya's mission is rooted in its belief that a patient-centric approach can drive positive outcomes, transforming clinical research into a more collaborative and fruitful endeavor for all involved.